l General Information |
Product Name | Axitinib |
General description | Axitinib is an orally bioavailable tyrosine kinase inhibitor. Axitinib inhibits the VEGF and PDGF, thereby exerting an anti-angiogenic effect. |
Synonym | N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide; AG-013736; AG 013736 |
Purity | ≥98%(HPLC) | CAS Number | 319460-85-0 |
Formula | C22H18N4OS | Molecular Weight | 386.473 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | White or Off-white solid |
Solubility(25℃) | DMSO | ≥20mg/mL |
Ethanol | Insoluble |
Water | Insoluble |
l Biological Information |
Biochem/Physiol Actions | Axitinib prevents the progression of cancer by inhibiting angiogenesis and blocking tumor growth. Axitinib is an orally bioavailable tyrosine kinase inhibitor. Axitinib inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor (PDGF), thereby exerting an anti-angiogenic effect. |
Application | Protein Kinase Inhibitors |
l Packaging & Storage |
Packaging | 25mg; 100mg; 500mg |
Storage temp. | 0-5℃ |
l Precautions and Disclaimer |
This product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
